HubSpot gets hit with a fresh bear call

Wall Street’s mood swing

HubSpot is having one of those days where the sell-side basically looks at the spreadsheet, sighs, and hits the bearish button. B of A Securities downgraded the CRM software name from Buy to Underperform and chopped its price target to $180 from $300. That’s not a trim — that’s a full-on buzzcut.

Why you should care

When analysts cut a stock’s target by that much, they’re usually saying some combo of: growth may slow, margins may not expand as fast as hoped, or the market was just paying too much for the story. For HubSpot, that matters because software names live and die on future expectations. If those expectations get pulled lower, the stock can feel like it got its wings clipped.

Not just a HubSpot story

This wasn’t a one-stock drama either. The same roundup included downgrades on Trade Desk, Vital Farms, Entrada Therapeutics, and Amphastar Pharmaceuticals. So it’s less “HubSpot-specific scandal” and more “Wall Street woke up cranky on Friday.”

• Trade Desk was cut from Outperform to Perform by Oppenheimer
• Vital Farms was downgraded from Buy to Hold by Stifel
• Entrada Therapeutics was cut from Buy to Neutral by HC Wainwright
• Amphastar Pharmaceuticals was downgraded from Buy to Hold by Needham

Big picture: HubSpot didn’t get singled out for a moonshot problem so much as a harsh reassessment of what investors should be willing to pay for the next leg of growth.